Saudi Arabia is key to the bull case after ImmunityBio launched Anktiva there for certain patients with bladder and lung cancer.

CULVER CITY, Calif.--(BUSINESS WIRE)-- ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced treatment with ANKTIVA® (nogapendekin alfa inbakicept-pmln) plus Bacillus ...

Anktiva plus BCG aims to treat BCG-unresponsive NMIBC with papillary disease, potentially reducing radical cystectomy need. The treatment showed high rates of surgery avoidance and disease-free ...

Outcomes over 36 months support nogapendekin alfa inbakicept plus BCG in papillary-only BCG unresponsive NMIBC with a high cystectomy-free rate. Combination treatment including the interleukin-15 ...

ImmunityBio seeks FDA approval to expand Anktiva use in papillary-only bladder cancer patients. IBRX resubmitted updated phase II/III data showing 58.2% 12-month disease-free survival. Anktiva sales ...

The MarketWatch News Department was not involved in the creation of this content. -- Following discussions with the U.S. FDA, the Agency recommended that the Company submit additional information for ...

In collaboration with University Hospital Basel, researchers from ETH are investigating the early stages of bladder cancer. Their findings show that future research should also focus on mechanical ...

ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced that the U.S. Food and Drug Administration has accepted for review the supplemental Biologics License ...

ImmunityBio Inc. (NASDAQ:IBRX) is one of the most buzzing stocks to buy with the highest upside potential. On March 9, ImmunityBio announced the resubmission of its sBLA to the FDA for ANKTIVA in ...

The pretzel-shaped gemcitabine intravesical system (formerly TAR-200) yields a high DFS rate among patients with papillary disease-only NMIBC -- including T1 – that fails to respond to BCG. The ...